SERBP1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 4.36761737887537E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.49509999936015E-08 |
Normal-vs-Stage2 |
2.080600E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.994350E-02 |
Stage1-vs-Stage2 |
4.457200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
1.734810E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.939000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
6.77039535545987E-11 |
Normal-vs-AfricanAmerican |
2.563800E-01 |
Normal-vs-Asian |
1.354170E-01 |
Caucasian-vs-AfricanAmerican |
1.508620E-01 |
Caucasian-vs-Asian |
8.681400E-01 |
AfricanAmerican-vs-Asian |
3.984600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.42309999995316E-06 |
Normal-vs-Female |
4.88470000004071E-07 |
Male-vs-Female |
5.391400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
7.965500E-04 |
Normal-vs-Extreme_Weight |
2.06469999999292E-05 |
Normal-vs-Obese |
5.808600E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
6.150000E-01 |
Normal_Weight-vs-Obese |
2.019800E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
4.436200E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
3.929400E-01 |
Normal-vs-Age(41-60Yrs) |
5.416100E-04 |
Normal-vs-Age(61-80Yrs) |
9.69619995405679E-09 |
Normal-vs-Age(81-100Yrs) |
4.102000E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.907800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.207000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.274800E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.232800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.451200E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.731000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
7.551400E-01 |
Normal-vs-Grade 3 |
7.893600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
8.712000E-01 |
Grade 2-vs-Grade 4 |
7.551400E-01 |
Grade 3-vs-Grade 4 |
7.893600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.40499945011641E-10 |
Normal-vs-N1 |
5.597600E-02 |
N0-vs-N1 |
7.280800E-01 |
|
|